PURPOSE: Mutations of the HFE gene that cause hereditary hemochromatosis may be associated with an increased risk of cardiovascular disease. We examined the relation between two HFE mutations (C282Y and H63D), indicators of iron homeostasis, and the prevalence of coronary heart disease in a large population of white adults. SUBJECTS AND METHODS: We conducted a cross-sectional study of 30,916 white adults aged 25 to 98 years who attended a health appraisal center and underwent screening for HFE mutations. Coronary heart disease and cardiovascular risk factors were ascertained by questionnaire and medical records. RESULTS: Overall, 12% (1798/15,362) of men and 7% (1074/15,554) of women had a history of coronary heart disease. Of 10 HFE genotypes tested (five genotypes by sex), only men with the C282Y/H63D genotype (compound heterozygotes) had a significantly higher prevalence of coronary heart disease compared with men with no HFE mutations (odds ratio = 1.6; 95% confidence interval: 1.1 to 2.4; P = 0.01) after adjusting for cardiovascular risk factors. Elevated serum ferritin levels (>250 ng/mL) were associated with a lower prevalence of coronary heart disease in men (10% [255/2209] vs. 12% [1515/12,461] in controls, P = 0.008), which was not significant after adjusting for use of aspirin and anticoagulants. There were no significant associations between elevated transferrin saturation in either men or women, or between elevated serum ferritin levels or HFE mutations in women, and the prevalence of coronary heart disease. CONCLUSION: The results do not support a consistent association between HFE mutations or serum iron indicators and the prevalence of coronary heart disease.
PURPOSE: Mutations of the HFE gene that cause hereditary hemochromatosis may be associated with an increased risk of cardiovascular disease. We examined the relation between two HFE mutations (C282Y and H63D), indicators of iron homeostasis, and the prevalence of coronary heart disease in a large population of white adults. SUBJECTS AND METHODS: We conducted a cross-sectional study of 30,916 white adults aged 25 to 98 years who attended a health appraisal center and underwent screening for HFE mutations. Coronary heart disease and cardiovascular risk factors were ascertained by questionnaire and medical records. RESULTS: Overall, 12% (1798/15,362) of men and 7% (1074/15,554) of women had a history of coronary heart disease. Of 10 HFE genotypes tested (five genotypes by sex), only men with the C282Y/H63D genotype (compound heterozygotes) had a significantly higher prevalence of coronary heart disease compared with men with no HFE mutations (odds ratio = 1.6; 95% confidence interval: 1.1 to 2.4; P = 0.01) after adjusting for cardiovascular risk factors. Elevated serum ferritin levels (>250 ng/mL) were associated with a lower prevalence of coronary heart disease in men (10% [255/2209] vs. 12% [1515/12,461] in controls, P = 0.008), which was not significant after adjusting for use of aspirin and anticoagulants. There were no significant associations between elevated transferrin saturation in either men or women, or between elevated serum ferritin levels or HFE mutations in women, and the prevalence of coronary heart disease. CONCLUSION: The results do not support a consistent association between HFE mutations or serum iron indicators and the prevalence of coronary heart disease.
Authors: Kuixing Zhang; Fangwen Rao; Lei Wang; Brinda K Rana; Sajalendu Ghosh; Manjula Mahata; Rany M Salem; Juan L Rodriguez-Flores; Maple M Fung; Jill Waalen; Bamidele Tayo; Laurent Taupenot; Sushil K Mahata; Daniel T O'Connor Journal: J Am Coll Cardiol Date: 2010-04-06 Impact factor: 24.094
Authors: Kuixing Zhang; Fangwen Rao; Jose Pablo Miramontes-Gonzalez; C Makena Hightower; Brian Vaught; Yuhong Chen; Tiffany A Greenwood; Andrew J Schork; Lei Wang; Manjula Mahata; Mats Stridsberg; Srikrishna Khandrika; Nilima Biswas; Maple M Fung; Jill Waalen; Rita P Middelberg; Andrew C Heath; Grant W Montgomery; Nicholas G Martin; John B Whitfield; Dewleen G Baker; Nicholas J Schork; Caroline M Nievergelt; Daniel T O'Connor Journal: J Am Coll Cardiol Date: 2012-09-26 Impact factor: 24.094
Authors: Yuqing Chen; Kuixing Zhang; Gen Wen; Fangwen Rao; Amber P Sanchez; Lei Wang; Juan L Rodriguez-Flores; Manjula Mahata; Sushil K Mahata; Jill Waalen; Michael G Ziegler; Bruce A Hamilton; Daniel T O'Connor Journal: Am J Hypertens Date: 2010-09-02 Impact factor: 2.689
Authors: Lian Zhang; Fangwen Rao; Kuixing Zhang; Srikrishna Khandrika; Madhusudan Das; Sucheta M Vaingankar; Xuping Bao; Brinda K Rana; Douglas W Smith; Jennifer Wessel; Rany M Salem; Juan L Rodriguez-Flores; Sushil K Mahata; Nicholas J Schork; Michael G Ziegler; Daniel T O'Connor Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808
Authors: Kuixing Zhang; Fangwen Rao; Brinda K Rana; Jiaur R Gayen; Federico Calegari; Angus King; Patrizia Rosa; Wieland B Huttner; Mats Stridsberg; Manjula Mahata; Sucheta Vaingankar; Vafa Mahboubi; Rany M Salem; Juan L Rodriguez-Flores; Maple M Fung; Douglas W Smith; Nicholas J Schork; Michael G Ziegler; Laurent Taupenot; Sushil K Mahata; Daniel T O'Connor Journal: Circ Cardiovasc Genet Date: 2009-02
Authors: Lei Wang; Fangwen Rao; Kuixing Zhang; Manjula Mahata; Juan L Rodriguez-Flores; Maple M Fung; Jill Waalen; Myles G Cockburn; Bruce A Hamilton; Sushil K Mahata; Daniel T O'Connor Journal: J Am Coll Cardiol Date: 2009-09-01 Impact factor: 24.094
Authors: Yuqing Chen; Fangwen Rao; Juan L Rodriguez-Flores; Manjula Mahata; Maple M Fung; Mats Stridsberg; Sucheta M Vaingankar; Gen Wen; Rany M Salem; Madhusudan Das; Myles G Cockburn; Nicholas J Schork; Michael G Ziegler; Bruce A Hamilton; Sushil K Mahata; Laurent Taupenot; Daniel T O'Connor Journal: J Am Coll Cardiol Date: 2008-10-28 Impact factor: 24.094
Authors: J J McCarthy; A Parker; R Salem; D J Moliterno; Q Wang; E F Plow; S Rao; G Shen; W J Rogers; L K Newby; R Cannata; K Glatt; E J Topol Journal: J Med Genet Date: 2004-05 Impact factor: 6.318